Evidence map›Paper›PMID 34354946›Full record

ArticleFrontiers in oncology2021

Evaluation of Microwave Ablation in 4T1 Breast Tumor by a Novel VEFGR2 Targeted Ultrasound Contrast Agents.

Xiaoyu Li, Shujun Xia, Ri Ji, Weiwei Zhan, Wei Zhou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Xiaoyu LiDepartment of Ultrasound, RuiJin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Shujun XiaDepartment of Ultrasound, RuiJin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Ri JiDepartment of Ultrasound, RuiJin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Weiwei ZhanDepartment of Ultrasound, RuiJin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Wei ZhouDepartment of Ultrasound, RuiJin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Ruijin Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesA novel ultrasound contrast agent (UCA) VEGFR2-targeting iron-doped silica (SiO

methodsVEGFR2-PEG-HSNs-Fe NPs were prepared by using nano-SiO

resultsThe average particle size of VEGFR2-PEG-HSNs-Fe was 276.64 ± 30.31 nm, and the surface potential was -13.46 ± 2.83 mV.

conclusionNano-targeted UCAs VEGFR2-PEG-HSNs-Fe NPs had good biosafety and ability of specific imaging, which might be used as a contrast agent in CEUS to evaluate the efficacy of tumor ablation.

Indexed as

breast cancercontrast enhanced ultrasoundmicrowave ablationultrasound contrast agentvascular endothelial growth factor receptor 2 targeted

Identifiers

PMID34354946
PMCPMC8329532
OpenAlexW3185091520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.